{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:42:47Z","timestamp":1790649767377,"version":"4.1.0"},"reference-count":160,"publisher":"Portland Press Ltd.","issue":"3","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,30]]},"abstract":"<jats:p>Polycystic Kidney Disease (PKD) refers to a group of disorders, driven by the formation of cysts in renal tubular cells and is currently one of the leading causes of end-stage renal disease. The range of symptoms observed in PKD is due to mutations in cilia-localising genes, resulting in changes in cellular signalling. As such, compounds that are currently in preclinical and clinical trials target some of these signalling pathways that are dysregulated in PKD. In this review, we highlight these pathways including cAMP, EGF and AMPK signalling and drugs that target them and may show promise in lessening the disease burden of PKD patients. At present, tolvaptan is the only approved therapy for ADPKD, however, it carries several adverse side effects whilst comparatively, no pharmacological drug is approved for ARPKD treatment. Aside from this, drugs that have been the subject of multiple clinical trials such as metformin, which targets AMPK signalling and somatostatins, which target cAMP signalling have shown great promise in reducing cyst formation and cellular proliferation. This review also discusses other potential and novel targets that can be used for future interventions, such as \u03b2-catenin and TAZ, where research has shown that a reduction in the overexpression of these signalling components results in amelioration of disease phenotype. Thus, it becomes apparent that well-designed preclinical investigations and future clinical trials into these pathways and other potential signalling targets are crucial in bettering disease prognosis for PKD patients and could lead to personalised therapy approaches.<\/jats:p>","DOI":"10.1042\/bst20200757","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T12:47:44Z","timestamp":1624366064000},"page":"1171-1188","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The cellular pathways and potential therapeutics of Polycystic Kidney Disease"],"prefix":"10.1042","volume":"49","author":[{"given":"Taylor","family":"Richards","sequence":"first","affiliation":[{"name":"Department of Biomedical Science and Physiology, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavindiya","family":"Modarage","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Physiology, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soniya A.","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Physiology, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-7747","authenticated-orcid":false,"given":"Paraskevi","family":"Goggolidou","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Physiology, Faculty of Science and Engineering, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"2021111916121048200_BST-2020-0757CC1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2021111916121048200_BST-2020-0757CC2","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","year":"2007","journal-title":"Lancet"},{"key":"2021111916121048200_BST-2020-0757CC3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fped.2017.00080","article-title":"Design and implementation of the hepatorenal fibrocystic disease core center clinical database: a centralized resource for characterizing autosomal recessive polycystic kidney disease and other hepatorenal fibrocystic diseases","volume":"5","year":"2017","journal-title":"Front. Pediatr."},{"key":"2021111916121048200_BST-2020-0757CC4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-013-2706-2","article-title":"ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies","volume":"30","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1523-1755.2005.00148.x","article-title":"Clinical consequences of PKHD1 mutations in 164 patients with autosomal-recessive polycystic kidney disease (ARPKD)","volume":"67","year":"2005","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC6","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1681\/ASN.V3121863","article-title":"Characteristics of very early onset autosomal dominant polycystic kidney disease","volume":"3","year":"1993","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1542\/peds.111.5.1072","article-title":"Autosomal recessive polycystic kidney disease: the clinical experience in North America","volume":"111","year":"2003","journal-title":"Pediatrics"},{"key":"2021111916121048200_BST-2020-0757CC8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/ajkd.2000.17619","article-title":"Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients","volume":"36","year":"2000","journal-title":"Am. J. Kidney. Dis."},{"key":"2021111916121048200_BST-2020-0757CC9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/jmg.30.7.583","article-title":"Childhood onset autosomal dominant polycystic kidney disease in sibs: clinical picture and recurrence risk. German working group on paediatric nephrology (Arbeitsgemeinschaft f\u00fcr p\u00e4diatrische nephrologie","volume":"30","year":"1993","journal-title":"J. Med. Genet."},{"key":"2021111916121048200_BST-2020-0757CC10","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1097\/01.ASN.0000029587.47950.25","article-title":"The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia","volume":"13","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC11","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1128\/MCB.00072-07","article-title":"Fibrocystin\/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia","volume":"27","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"2021111916121048200_BST-2020-0757CC12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0092-8674(95)90339-9","article-title":"Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The international polycystic kidney disease consortium","volume":"81","author":"The International Polycystic Kidney Disease Consortium","year":"1995","journal-title":"Cell"},{"key":"2021111916121048200_BST-2020-0757CC13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","year":"1996","journal-title":"Science"},{"key":"2021111916121048200_BST-2020-0757CC14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ng833","article-title":"The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein","volume":"30","year":"2002","journal-title":"Nat. Genet."},{"key":"2021111916121048200_BST-2020-0757CC15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ng.3871","article-title":"Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease","volume":"49","year":"2017","journal-title":"Nat. Genet."},{"key":"2021111916121048200_BST-2020-0757CC16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1083\/jcb.200910096","article-title":"The cytoplasmic tail of fibrocystin contains a ciliary targeting sequence","volume":"188","year":"2010","journal-title":"J. Cell Biol."},{"key":"2021111916121048200_BST-2020-0757CC17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/j.1523-1755.2004.00844.x","article-title":"Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm","volume":"66","year":"2004","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","year":"2003","journal-title":"Nat. Genet."},{"key":"2021111916121048200_BST-2020-0757CC19","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0960-9822(02)00877-1","article-title":"Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease","volume":"12","year":"2002","journal-title":"Curr. Biol."},{"key":"2021111916121048200_BST-2020-0757CC20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/01.ASN.0000113793.12558.1D","article-title":"The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area","volume":"15","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC21","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1093\/hmg\/ddg274","article-title":"Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia","volume":"12","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"2021111916121048200_BST-2020-0757CC22","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1073\/pnas.0400073101","article-title":"PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells","volume":"101","year":"2004","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111916121048200_BST-2020-0757CC23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1681\/ASN.2007070770","article-title":"Fibrocystin\/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function","volume":"19","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC24","doi-asserted-by":"publisher","first-page":"31559","DOI":"10.1074\/jbc.M805452200","article-title":"Polycystin-2 expression is regulated by a PC2-binding domain in the intracellular portion of fibrocystin","volume":"283","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2021111916121048200_BST-2020-0757CC25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature17426","article-title":"Primary cilia are not calcium-responsive mechanosensors","volume":"531","year":"2016","journal-title":"Nature"},{"key":"2021111916121048200_BST-2020-0757CC26","doi-asserted-by":"publisher","first-page":"6397","DOI":"10.1073\/pnas.94.12.6397","article-title":"Polycystin: in vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein","volume":"94","year":"1997","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111916121048200_BST-2020-0757CC27","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1093\/hmg\/9.18.2743","article-title":"Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells","volume":"9","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"2021111916121048200_BST-2020-0757CC28","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1242\/jcs.045021","article-title":"Homophilic and heterophilic polycystin 1 interactions regulate E-cadherin recruitment and junction assembly in MDCK cells","volume":"122","year":"2009","journal-title":"J. Cell Sci."},{"key":"2021111916121048200_BST-2020-0757CC29","doi-asserted-by":"publisher","first-page":"28557","DOI":"10.1074\/jbc.274.40.28557","article-title":"Identification and characterization of polycystin-2, thePKD2 gene product","volume":"274","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2021111916121048200_BST-2020-0757CC30","doi-asserted-by":"publisher","first-page":"29728","DOI":"10.1074\/jbc.M400544200","article-title":"PKD2 interacts and co-localizes with mDia1 to mitotic spindles of dividing cells: role of mDia1 in PKD2 localization to mitotic spindles","volume":"279","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021111916121048200_BST-2020-0757CC31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/hmg\/11.1.59","article-title":"Distinct subcellular expression of endogenous polycystin-2 in the plasma membrane and Golgi apparatus of MDCK cells","volume":"11","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"2021111916121048200_BST-2020-0757CC32","doi-asserted-by":"publisher","first-page":"41298","DOI":"10.1074\/jbc.M510082200","article-title":"Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling","volume":"280","year":"2005","journal-title":"J. Biol. Chem"},{"key":"2021111916121048200_BST-2020-0757CC33","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1093\/hmg\/ddq233","article-title":"Polycystic kidney disease protein fibrocystin localizes to the mitotic spindle and regulates spindle bipolarity","volume":"19","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"2021111916121048200_BST-2020-0757CC34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.kint.2017.04.027","article-title":"A novel model of autosomal recessive polycystic kidney questions the role of the fibrocystin C-terminus in disease mechanism","volume":"92","year":"2017","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC35","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1681\/ASN.2008060564","article-title":"Characterization of PKD protein-positive exosome-like vesicles","volume":"20","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0070-2153(08)00606-6","article-title":"Mouse models of polycystic kidney disease","volume":"84","year":"2008","journal-title":"Curr. Top. Dev. Biol"},{"key":"2021111916121048200_BST-2020-0757CC37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrneph.2014.137","article-title":"Translational research in ADPKD: lessons from animal models","volume":"10","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC38","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00335-016-9633-z","article-title":"High-resolution genetic localization of a modifying locus affecting disease severity in the juvenile cystic kidneys (jck) mouse model of polycystic kidney disease","volume":"27","year":"2016","journal-title":"Mamm. Genome"},{"key":"2021111916121048200_BST-2020-0757CC39","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1681\/ASN.2005060645","article-title":"Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells","volume":"17","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC41","doi-asserted-by":"publisher","first-page":"e0177934","DOI":"10.1371\/journal.pone.0177934","article-title":"Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease","volume":"12","year":"2017","journal-title":"PLoS ONE"},{"key":"2021111916121048200_BST-2020-0757CC42","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1111\/j.1523-1755.2004.00952.x","article-title":"Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats","volume":"66","year":"2004","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC43","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/MPG.0b013e3181cc80e4","article-title":"Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK Rat model of autosomal recessive polycystic kidney disease","volume":"50","year":"2010","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"2021111916121048200_BST-2020-0757CC44","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.ajpath.2018.06.014","article-title":"Blockade of hedgehog signaling attenuates biliary cystogenesis in the polycystic kidney (PCK) Rat","volume":"188","year":"2018","journal-title":"Am. J. Pathol."},{"key":"2021111916121048200_BST-2020-0757CC45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1046\/j.1523-1755.2001.00473.x","article-title":"The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease","volume":"59","year":"2001","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC46","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","year":"2003","journal-title":"Nat. Med."},{"key":"2021111916121048200_BST-2020-0757CC47","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease","volume":"17","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC48","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1046\/j.1523-1755.2003.00232.x","article-title":"Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability","volume":"64","year":"2003","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC49","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5527\/wjn.v6.i4.188","article-title":"Tesevatinib ameliorates progression of polycystic kidney disease in rodent models of autosomal recessive polycystic kidney disease","volume":"6","year":"2017","journal-title":"World J. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC50","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00335-002-2241-0","article-title":"Positional cloning of jcpk\/bpk locus of the mouse","volume":"14","year":"2003","journal-title":"Mamm. Genome"},{"key":"2021111916121048200_BST-2020-0757CC51","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1111\/j.1523-1755.2004.00623.x","article-title":"EGF-related growth factors in the pathogenesis of murine ARPKD","volume":"65","year":"2004","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC52","doi-asserted-by":"publisher","first-page":"F187","DOI":"10.1152\/ajprenal.00051.2019","article-title":"A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Pkd1 mouse model of autosomal dominant polycystic kidney disease","volume":"317","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S238767","article-title":"Regression of peritubular capillaries coincides with angiogenesis and renal cyst growth in experimental polycystic kidney disease","volume":"13","year":"2020","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"2021111916121048200_BST-2020-0757CC54","doi-asserted-by":"publisher","first-page":"e0209186","DOI":"10.1371\/journal.pone.0209186","article-title":"Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease","volume":"14","year":"2019","journal-title":"PLoS ONE"},{"key":"2021111916121048200_BST-2020-0757CC55","doi-asserted-by":"publisher","first-page":"F1223","DOI":"10.1152\/ajprenal.00697.2016","article-title":"Aberrant Smad3 phosphoisoforms in cyst-lining epithelial cells in the cpk mouse, a model of autosomal recessive polycystic kidney disease","volume":"313","year":"2017","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC56","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/ki.2014.427","article-title":"Glycogen cyst expansion in polycystic kidney disease","volume":"87","year":"2015","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC57","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/hmg\/9.5.769","article-title":"Germline and somatic loss of function of the mouse cpk gene causes biliary ductal pathology that is genetically modulated","volume":"9","year":"2000","journal-title":"Hum. Mol. Genet"},{"key":"2021111916121048200_BST-2020-0757CC58","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1681\/ASN.V11101837","article-title":"Development of autosomal recessive polycystic kidney disease in BALB\/c-cpk\/cpk mice","volume":"11","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model","volume":"26","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC60","doi-asserted-by":"publisher","first-page":"F1135","DOI":"10.1152\/ajprenal.00366.2020","article-title":"Overexpression of TGF-\u03b21 induces renal fibrosis and accelerates the decline in kidney function in polycystic kidney disease","volume":"319","year":"2020","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/path.2734","article-title":"Elevated TGF\u03b2-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease","volume":"222","year":"2010","journal-title":"J. Pathol."},{"key":"2021111916121048200_BST-2020-0757CC62","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1681\/ASN.2013070735","article-title":"Downregulating hedgehog signaling reduces renal cystogenic potential of mouse models","volume":"25","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC63","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021111916121048200_BST-2020-0757CC64","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000448693","article-title":"Dose-Titrated vasopressin V2 receptor antagonist improves renoprotection in a mouse model for autosomal dominant polycystic kidney disease","volume":"44","year":"2016","journal-title":"Ame. J. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC65","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ebiom.2019.08.041","article-title":"Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease","volume":"47","year":"2019","journal-title":"EBioMedicine"},{"key":"2021111916121048200_BST-2020-0757CC66","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1101\/gad.315127.118","article-title":"A rhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease","volume":"32","year":"2018","journal-title":"Genes Dev."},{"key":"2021111916121048200_BST-2020-0757CC67","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.bbadis.2018.11.003","article-title":"Atmin modulates Pkhd1 expression and may mediate autosomal recessive polycystic kidney disease (ARPKD) through altered non-canonical Wnt\/Planar cell polarity (PCP) signalling","volume":"1865","year":"2019","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111916121048200_BST-2020-0757CC68","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells 1","volume":"66","year":"2004","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC69","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1681\/ASN.V1171179","article-title":"cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells","volume":"11","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC70","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","article-title":"cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway 1","volume":"57","year":"2000","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC71","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","year":"2003","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC72","doi-asserted-by":"publisher","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","year":"2004","journal-title":"J. Biol. Chem."},{"key":"2021111916121048200_BST-2020-0757CC73","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1681\/ASN.V124719","article-title":"Role of CFTR in autosomal recessive polycystic kidney disease","volume":"12","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC74","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","article-title":"Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease","volume":"30","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"2021111916121048200_BST-2020-0757CC75","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/ki.1996.304","article-title":"The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro","volume":"50","year":"1996","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1152\/ajpcell.1996.270.1.C389","article-title":"A role for CFTR in human autosomal dominant polycystic kidney disease","volume":"270","year":"1996","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021111916121048200_BST-2020-0757CC77","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4&lt;309::AID-DVG14&gt;3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease","volume":"24","year":"1999","journal-title":"Dev. Genet."},{"key":"2021111916121048200_BST-2020-0757CC78","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1681\/ASN.2007060665","article-title":"Src inhibition ameliorates polycystic kidney disease","volume":"19","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC79","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC80","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a Rat model of polycystic kidney disease","volume":"16","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC81","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)","volume":"21","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021111916121048200_BST-2020-0757CC82","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/ki.2010.250","article-title":"Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease","volume":"78","year":"2010","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC83","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/ndt\/gfu296","article-title":"An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease","volume":"30","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021111916121048200_BST-2020-0757CC84","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1038\/s41598-019-41106-3","article-title":"Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis","volume":"9","year":"2019","journal-title":"Sci. Rep."},{"key":"2021111916121048200_BST-2020-0757CC85","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1093\/hmg\/ddr338","article-title":"Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways","volume":"20","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"2021111916121048200_BST-2020-0757CC86","doi-asserted-by":"publisher","first-page":"109639","DOI":"10.1016\/j.cellsig.2020.109639","article-title":"STAT signaling in polycystic kidney disease","volume":"72","year":"2020","journal-title":"Cell Signal."},{"key":"2021111916121048200_BST-2020-0757CC87","doi-asserted-by":"publisher","first-page":"e95874","DOI":"10.1172\/jci.insight.95874","article-title":"Canonical Wnt inhibitors ameliorate cystogenesis in a mouse ortholog of human ADPKD","volume":"3","year":"2018","journal-title":"JCI Insight"},{"key":"2021111916121048200_BST-2020-0757CC88","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ncb3363","article-title":"The polycystin complex mediates Wnt\/Ca2+ signalling","volume":"18","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"2021111916121048200_BST-2020-0757CC89","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/ng.179","article-title":"Loss of Fat4 disrupts PCP signaling and oriented cell division and leads to cystic kidney disease","volume":"40","year":"2008","journal-title":"Nat. Genet."},{"key":"2021111916121048200_BST-2020-0757CC90","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3389\/fcell.2020.00811","article-title":"SNX9 inhibits cell proliferation and cyst development in autosomal dominant polycystic kidney disease via activation of the hippo-YAP signaling pathway","volume":"8","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"2021111916121048200_BST-2020-0757CC91","doi-asserted-by":"publisher","first-page":"29001","DOI":"10.1073\/pnas.2009334117","article-title":"TAZ\/Wnt-\u03b2-catenin\/c-MYC axis regulates cystogenesis in polycystic kidney disease","volume":"117","year":"2020","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111916121048200_BST-2020-0757CC92","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1096\/fj.201701376RR","article-title":"Scribble influences cyst formation in autosomal-dominant polycystic kidney disease by regulating hippo signaling pathway","volume":"32","year":"2018","journal-title":"FASEB J."},{"key":"2021111916121048200_BST-2020-0757CC93","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1038\/s41598-018-23341-2","article-title":"Inhibition of hedgehog signaling suppresses proliferation and microcyst formation of human autosomal dominant polycystic kidney disease cells","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"key":"2021111916121048200_BST-2020-0757CC94","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?","volume":"19","year":"2018","journal-title":"BMC Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC95","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12882-019-1463-2","article-title":"A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease","volume":"20","year":"2019","journal-title":"BMC Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC96","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000488807","article-title":"A randomized clinical trial of metformin to treat autosomal dominant polycystic kidney disease","volume":"47","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC97","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41598-020-58382-z","article-title":"Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective","volume":"10","year":"2020","journal-title":"Sci. Rep."},{"key":"2021111916121048200_BST-2020-0757CC98","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1515\/jtim-2016-0028","article-title":"Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor \u03b3 agonists","volume":"4","year":"2016","journal-title":"J. Transl. Int. Med."},{"key":"2021111916121048200_BST-2020-0757CC99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/labinvest.2008.104","article-title":"PPAR-\u03b3 agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-\u03b2","volume":"89","year":"2009","journal-title":"Lab. Invest."},{"key":"2021111916121048200_BST-2020-0757CC100","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1042\/CS20100113","article-title":"Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats","volume":"119","year":"2010","journal-title":"Clin. Sci. (Lond)"},{"key":"2021111916121048200_BST-2020-0757CC101","doi-asserted-by":"publisher","first-page":"274376","DOI":"10.1155\/2010\/274376","article-title":"Pioglitazone attenuates cystic burden in the PCK rodent model of polycystic kidney disease","volume":"2010","year":"2010","journal-title":"PPAR Res."},{"key":"2021111916121048200_BST-2020-0757CC102","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000242432","article-title":"Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease","volume":"30","year":"2009","journal-title":"Am. J. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC103","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/hmg\/11.15.1731","article-title":"Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant","volume":"11","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"2021111916121048200_BST-2020-0757CC104","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1152\/ajpcell.1995.269.2.C487","article-title":"Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD","volume":"269","year":"1995","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021111916121048200_BST-2020-0757CC105","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.bbadis.2006.04.006","article-title":"Inhibition of HER-2(neu\/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia","volume":"1762","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111916121048200_BST-2020-0757CC106","doi-asserted-by":"publisher","first-page":"F387","DOI":"10.1152\/ajprenal.1998.275.3.F387","article-title":"Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease","volume":"44","year":"1998","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC107","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1681\/ASN.V122379","article-title":"Segment-specific c-ErbB2 expression in human autosomal recessive polycystic kidney disease","volume":"12","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC108","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1046\/j.1523-1755.2001.00963.x","article-title":"A novel inhibitor of tumor necrosis factor-\u03b1 converting enzyme ameliorates polycystic kidney disease","volume":"60","year":"2001","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC109","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ki.1995.62","article-title":"Epidermal growth factor receptor expression is abnormal in murine polycystic kidney","volume":"47","year":"1995","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1523-1755.2000.00829.x","article-title":"Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor 1","volume":"57","year":"2000","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC111","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1172\/JCI2071","article-title":"Role of epidermal growth factor receptor in polycystic kidney disease rapid publication epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease","volume":"101","year":"1998","journal-title":"J. Clin. Invest."},{"key":"2021111916121048200_BST-2020-0757CC112","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1046\/j.1523-1755.2003.00256.x","article-title":"EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats","volume":"64","year":"2003","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC113","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1152\/ajpcell.2001.281.5.C1695","article-title":"Phenotypic analysis of conditionally immortalized cells isolated from the BPK model of ARPKD","volume":"281","year":"2001","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021111916121048200_BST-2020-0757CC114","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0022-5347(01)67652-3","article-title":"Epidermal growth factor precursor is present in a variety of human renal cyst fluids","volume":"153","year":"1995","journal-title":"J. Urol."},{"key":"2021111916121048200_BST-2020-0757CC115","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0272-6386(12)80212-5","article-title":"Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis","volume":"24","year":"1994","journal-title":"Am. J. Kidney Dis."},{"key":"2021111916121048200_BST-2020-0757CC116","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1152\/ajprenal.00038.2010","article-title":"Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease","volume":"300","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC117","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan inhibits ERK-dependent cell proliferation, Cl\u2212 secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin","volume":"301","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC118","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC119","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/ki.2011.119","article-title":"Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease","volume":"80","year":"2011","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC120","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2021111916121048200_BST-2020-0757CC121","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC122","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and european renal best practice","volume":"31","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021111916121048200_BST-2020-0757CC123","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","year":"2013","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC124","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1159\/000500667","article-title":"Effect of a vasopressin V2 receptor antagonist on polycystic kidney disease development in a Rat model","volume":"49","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC125","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/ndt\/gfz054","article-title":"Somatostatin in renal physiology and autosomal dominant polycystic kidney disease","volume":"35","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021111916121048200_BST-2020-0757CC126","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","year":"2013","journal-title":"Hepatology"},{"key":"2021111916121048200_BST-2020-0757CC127","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1002\/hep.25872","article-title":"Cyclic AMP\/PKA-dependent paradoxical activation of Raf\/MEK\/ERK signaling in polycystin-2 defective mice treated with sorafenib","volume":"56","year":"2012","journal-title":"Hepatology"},{"key":"2021111916121048200_BST-2020-0757CC128","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","year":"2005","journal-title":"Kidney Int."},{"key":"2021111916121048200_BST-2020-0757CC129","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","year":"2018","journal-title":"JAMA"},{"key":"2021111916121048200_BST-2020-0757CC130","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1152\/ajpcell.00163.2010","article-title":"c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation","volume":"301","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021111916121048200_BST-2020-0757CC131","doi-asserted-by":"publisher","first-page":"12451","DOI":"10.1002\/jcp.28094","article-title":"Autosomal dominant polycystic kidney disease: disrupted pathways and potential therapeutic interventions","volume":"234","year":"2019","journal-title":"J. Cell Physiol."},{"key":"2021111916121048200_BST-2020-0757CC132","doi-asserted-by":"publisher","first-page":"100635","DOI":"10.1016\/j.conctc.2020.100635","article-title":"Curcumin therapy to treat vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease: design and baseline characteristics of participants","volume":"19","year":"2020","journal-title":"Contemp. Clin. Trials Commun."},{"key":"2021111916121048200_BST-2020-0757CC133","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.ajkd.2014.01.418","article-title":"Triptolide-containing formulation in patients with autosomal dominant polycystic kidney disease and proteinuria: an uncontrolled trial","volume":"63","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"2021111916121048200_BST-2020-0757CC134","doi-asserted-by":"publisher","first-page":"F479","DOI":"10.1152\/ajprenal.00329.2017","article-title":"Triptolide delays disease progression in an adult rat model of polycystic kidney disease through the JAK2-STAT3 pathway","volume":"315","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC135","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1158\/0008-5472.CAN-12-1702","article-title":"Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR","volume":"73","year":"2013","journal-title":"Cancer Res."},{"key":"2021111916121048200_BST-2020-0757CC136","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2021111916121048200_BST-2020-0757CC137","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2021111916121048200_BST-2020-0757CC138","doi-asserted-by":"publisher","first-page":"e87660","DOI":"10.1371\/journal.pone.0087660","article-title":"Activation of the PI3K\/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat","volume":"9","year":"2014","journal-title":"PLoS ONE"},{"key":"2021111916121048200_BST-2020-0757CC139","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/path.5286","article-title":"Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury","volume":"249","year":"2019","journal-title":"J. Pathol."},{"key":"2021111916121048200_BST-2020-0757CC140","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","year":"2008","journal-title":"Mol. Cell"},{"key":"2021111916121048200_BST-2020-0757CC141","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1172\/JCI9622","article-title":"Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase","volume":"105","year":"2000","journal-title":"J. Clin. Invest."},{"key":"2021111916121048200_BST-2020-0757CC142","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","year":"2011","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021111916121048200_BST-2020-0757CC143","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/liv.12726","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial","volume":"35","year":"2015","journal-title":"Liver Int."},{"key":"2021111916121048200_BST-2020-0757CC144","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.xkme.2019.11.009","article-title":"Advances in autosomal dominant polycystic kidney disease: a clinical review","volume":"2","year":"2020","journal-title":"Kidney Med."},{"key":"2021111916121048200_BST-2020-0757CC145","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111916121048200_BST-2020-0757CC146","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1038\/s41598-020-61082-3","article-title":"A high-throughput screening platform for polycystic kidney disease (PKD) drug repurposing utilizing murine and human ADPKD cells","volume":"10","year":"2020","journal-title":"Sci. Rep."},{"key":"2021111916121048200_BST-2020-0757CC147","doi-asserted-by":"publisher","first-page":"BSR20203121","DOI":"10.1042\/BSR20203121","article-title":"The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis","volume":"41","year":"2021","journal-title":"Biosci. Rep."},{"key":"2021111916121048200_BST-2020-0757CC148","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1124\/mol.115.099549","article-title":"AMPK inhibits the stimulatory effects of TGF-\u03b2 on Smad2\/3 activity, cell migration, and epithelial-to-mesenchymal transition","volume":"88","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"2021111916121048200_BST-2020-0757CC149","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncb3113","article-title":"AMPK modulates hippo pathway activity to regulate energy homeostasis","volume":"17","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"2021111916121048200_BST-2020-0757CC150","doi-asserted-by":"publisher","first-page":"5972","DOI":"10.1038\/sj.onc.1204825","article-title":"Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene","volume":"20","year":"2001","journal-title":"Oncogene"},{"key":"2021111916121048200_BST-2020-0757CC151","doi-asserted-by":"publisher","first-page":"104751","DOI":"10.1016\/j.phrs.2020.104751","article-title":"Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis","volume":"155","year":"2020","journal-title":"Pharmacol. Res."},{"key":"2021111916121048200_BST-2020-0757CC152","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/978-3-319-51436-9_11","article-title":"Primary cilia in cystic kidney disease","volume":"60","year":"2017","journal-title":"Results Probl. Cell Differ."},{"key":"2021111916121048200_BST-2020-0757CC153","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1152\/ajprenal.00460.2010","article-title":"PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease","volume":"300","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2021111916121048200_BST-2020-0757CC154","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bbadis.2011.01.006","article-title":"Apoptosis in polycystic kidney disease","volume":"1812","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"2021111916121048200_BST-2020-0757CC155","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.yexcr.2010.09.012","article-title":"Cystogenesis in ARPKD results from increased apoptosis in collecting duct epithelial cells of Pkhd1 mutant kidneys","volume":"317","year":"2011","journal-title":"Exp. Cell Res."},{"key":"2021111916121048200_BST-2020-0757CC156","doi-asserted-by":"publisher","first-page":"695898","DOI":"10.1155\/2012\/695898","article-title":"Global gene expression profiling in PPAR-\u03b3 agonist-treated kidneys in an orthologous rat model of human autosomal recessive polycystic kidney disease","volume":"2012","year":"2012","journal-title":"PPAR Res."},{"key":"2021111916121048200_BST-2020-0757CC157","doi-asserted-by":"publisher","first-page":"7733","DOI":"10.1038\/s41598-017-08284-4","article-title":"NEDD4-family e3 ligase dysfunction due to PKHD1\/Pkhd1 defects suggests a mechanistic model for ARPKD pathobiology","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"key":"2021111916121048200_BST-2020-0757CC158","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","year":"2017","journal-title":"Front. Pharmacol."},{"key":"2021111916121048200_BST-2020-0757CC159","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/ndt\/gfw058","article-title":"Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor \u03baB-induced inflammation","volume":"31","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"2021111916121048200_BST-2020-0757CC160","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/nu11071624","article-title":"Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies","volume":"11","year":"2019","journal-title":"Nutrients"}],"container-title":["Biochemical Society Transactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/49\/3\/1171\/916001\/bst-2020-0757c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article-pdf\/49\/3\/1171\/916001\/bst-2020-0757c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T16:31:44Z","timestamp":1637339504000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsoctrans\/article\/49\/3\/1171\/229086\/The-cellular-pathways-and-potential-therapeutics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":160,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,6,22]]},"published-print":{"date-parts":[[2021,6,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bst20200757","relation":{},"ISSN":["0300-5127","1470-8752"],"issn-type":[{"value":"0300-5127","type":"print"},{"value":"1470-8752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}